Form 4: BiomX Inc. Executive Merav Bassan Reports Stock and Options Transactions

Merav Bassan, Chief Development Officer of BiomX Inc., reports the acquisition of restricted stock units and options, along with the disposal of common stock.

Summary

• Merav Bassan, the Chief Development Officer of BiomX Inc., filed a Form 4 detailing changes in beneficial ownership.
• On April 14, 2025, Bassan acquired 79,597 Restricted Stock Units (RSUs) that are immediately vested and convert into common stock on a one-for-one basis.
• Bassan also acquired options to purchase 95,000 shares of common stock at an exercise price of $0.538.
• These options vest over four years, with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.
• Bassan also disposed of 79,597 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock and option grants.

Positives

• The grant of RSUs and options to the Chief Development Officer suggests an incentive to align her interests with the company's long-term success.

Future Outlook

The vesting schedule of the options indicates a multi-year commitment from the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Key Dates

Keywords

Form 4, BiomX Inc., Merav Bassan, Restricted Stock Units, Options, Beneficial Ownership, PHGE, Chief Development Officer